Trastuzumab induces tumour regression in approximately 30–35% of patients with HER2-amplified metastatic breast cancer if used as up-front therapy and much less activity if used after other chemotherapies (Tokunaga et al, 2006b). The gene discussed is ERBB2; the disease is neoplasm.